Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,042 | -1,654 | -5,447 | -4,082 | -2,684 |
| Depreciation Amortization | 495 | 260 | 2,330 | 2,078 | 1,378 |
| Accounts payable and accrued liabilities | 66 | 191 | -793 | -590 | -316 |
| Other Working Capital | -19 | 99 | -806 | -576 | -366 |
| Other Operating Activity | 452 | 68 | 1,275 | 813 | 469 |
| Operating Cash Flow | $-2,048 | $-1,036 | $-3,441 | $-2,357 | $-1,519 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 3,602 | 3,602 | 223 |
| Common Stock Issued | N/A | N/A | 3,058 | 3,058 | 3,058 |
| Other Financing Activity | 183 | 220 | 0 | 0 | 0 |
| Financing Cash Flow | $183 | $220 | $6,660 | $6,660 | $3,281 |
| Beginning Cash Position | 4,491 | 4,491 | 1,272 | 1,272 | 1,272 |
| End Cash Position | 2,626 | 3,675 | 4,491 | 5,575 | 3,034 |
| Net Cash Flow | $-1,865 | $-816 | $3,219 | $4,303 | $1,762 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,048 | -1,036 | -3,441 | -2,357 | -1,519 |
| Free Cash Flow | -2,048 | -1,036 | -3,441 | -2,357 | -1,519 |